A citation-based method for searching scientific literature


List of co-cited articles
902 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
M B Toft-Nielsen, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst. J Clin Endocrinol Metab 2001
612
18

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
18

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
862
18


Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M A Nauck, I Vardarli, C F Deacon, J J Holst, J J Meier. Diabetologia 2011
300
15


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
13

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
562
13


Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.
S Calanna, M Christensen, J J Holst, B Laferrère, L L Gluud, T Vilsbøll, F K Knop. Diabetologia 2013
144
12

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
12

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
12


Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Filip K Knop, Tina Vilsbøll, Patricia V Højberg, Steen Larsen, Sten Madsbad, Aage Vølund, Jens J Holst, Thure Krarup. Diabetes 2007
214
12


GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.
Kristine Færch, Signe S Torekov, Dorte Vistisen, Nanna B Johansen, Daniel R Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Annelli Sandbæk,[...]. Diabetes 2015
137
10

Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
9

Impaired regulation of the incretin effect in patients with type 2 diabetes.
Jonatan I Bagger, Filip K Knop, Asger Lund, Henrik Vestergaard, Jens J Holst, Tina Vilsbøll. J Clin Endocrinol Metab 2011
132
9


Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.
Nils B Jørgensen, Carsten Dirksen, Kirstine N Bojsen-Møller, Siv H Jacobsen, Dorte Worm, Dorte L Hansen, Viggo B Kristiansen, Lars Naver, Sten Madsbad, Jens J Holst. Diabetes 2013
185
9


Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.
R Eissele, R Göke, S Willemer, H P Harthus, H Vermeer, R Arnold, B Göke. Eur J Clin Invest 1992
439
9


GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Nikolaos Mentis, Irfan Vardarli, Lars D Köthe, Jens J Holst, Carolyn F Deacon, Michael Theodorakis, Juris J Meier, Michael A Nauck. Diabetes 2011
94
8

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
297
8

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
C Orskov, L Rabenhøj, A Wettergren, H Kofod, J J Holst. Diabetes 1994
706
8


Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
723
8

Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes.
Gang Xu, Hideaki Kaneto, D Ross Laybutt, Valerie F Duvivier-Kali, Nitin Trivedi, Kiyoshi Suzuma, George L King, Gordon C Weir, Susan Bonner-Weir. Diabetes 2007
257
8

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.
Salvatore Calanna, Mikkel Christensen, Jens J Holst, Blandine Laferrère, Lise L Gluud, Tina Vilsbøll, Filip K Knop. Diabetes Care 2013
85
9


Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
700
7

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Filip K Knop, K Aaboe, T Vilsbøll, A Vølund, J J Holst, T Krarup, S Madsbad. Diabetes Obes Metab 2012
106
7





A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.
C Verdich, A Flint, J P Gutzwiller, E Näslund, C Beglinger, P M Hellström, S J Long, L M Morgan, J J Holst, A Astrup. J Clin Endocrinol Metab 2001
403
7

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
7

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
121
7


GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
375
7


Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
Elza Muscelli, Andrea Mari, Arturo Casolaro, Stefania Camastra, Giuseppe Seghieri, Amalia Gastaldelli, Jens J Holst, Ele Ferrannini. Diabetes 2008
251
6

GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery.
Amanda Jiménez, Roser Casamitjana, Judith Viaplana-Masclans, Antonio Lacy, Josep Vidal. Diabetes Care 2013
80
7


Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst. J Clin Endocrinol Metab 2003
363
6

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
352
6

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.